文献速递临床试验与 GCP基础与转化研究

DAWn-Antico研究:COVID-19宿主血栓炎症反应调节的随机开放标签适应性概念验证临床试验

A randomized, open-label, adaptive, proof-of-concept clinical trial of modulation of host thromboinflammatory response in patients with COVID-19: the DAWn-Antico study.
PubMed 文献 · Trials · 2020-12-09

该研究为适应性、开放标签、多中心随机临床试验,比较低分子肝素(50 IU anti-Xa/kg每日两次,ICU患者75 IU anti-Xa每日两次)联合抑肽酶与标准血栓预防在住院COVID-19患者中的效果,高炎症时加用阿那白滞素。试点阶段评估对D-二聚体的影响,全试验主要结局为WHO临床改善序贯量表定义的临床状态变化。

要点

  • 针对COVID-19血栓炎症反应,试验联合低分子肝素、抑肽酶,高炎症时加阿那白滞素。
  • 主要结局为WHO序贯量表临床状态变化,试点阶段评估D-二聚体。
  • 抑肽酶抑制激肽释放酶通路,体外显示抑制SARS-CoV-2细胞进入。

核心结论

  • 假设凝血接触通路和激肽释放酶-缓激肽通路在重症COVID-19中起关键病理生理作用,调节过度血栓炎症反应可能改善预后。

研究设计与样本

  • 适应性、开放标签、多中心随机临床试验,比较低分子肝素联合抑肽酶与标准血栓预防,高炎症时干预组加用阿那白滞素。
  • 试点阶段评估干预对血栓标志物D-二聚体的影响,全试验主要结局为WHO临床改善序贯量表定义的临床状态。

关键数值与推荐

  • 低分子肝素剂量:50 IU anti-Xa/kg每日两次,ICU患者为75 IU anti-Xa每日两次。
  • 高炎症时在干预组药物基础上加用白介素-1受体拮抗剂阿那白滞素。
  • 主要结局指标为WHO临床改善序贯量表评估的临床状态变化。

临床怎么用

  • 针对住院COVID-19患者,可考虑在标准血栓预防基础上强化低分子肝素剂量并联合抑肽酶。
  • 对炎症参数显著升高的患者,可加用阿那白滞素以调节过度血栓炎症反应。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The peak of the global COVID-19 pandemic has not yet been reached, and many countries face the prospect of a second wave of infections before effective vaccinations will be available. After an initial phase of viral replication, some patients develop a second illness phase in which the host thrombotic and inflammatory responses seem to drive complications. Severe COVID-19 disease is linked to high mortality, hyperinflammation, and a remarkably high incidence of thrombotic events. We hypothesize a crucial pathophysiological role for the contact pathway of coagulation and the kallikrein-bradykinin pathway. Therefore, drugs that modulate this excessive thromboinflammatory response should be investigated in severe COVID-19. METHODS: In this adaptive, open-label multicenter randomized clinical trial, we compare low molecular weight heparins at 50 IU anti-Xa/kg twice daily-or 75 IU anti-Xa twice daily for intensive care (ICU) patients-in combination with aprotinin to standard thromboprophylaxis in hospitalized COVID-19 patients. In the case of hyperinflammation, the interleukin-1 receptor antagonist anakinra will be added on top of the drugs in the interventional arm. In a pilot phase, the effect of the intervention on thrombotic markers (D-dimer) will be assessed. In the full trial, the primary outcome is defined as the effect of the interventional drugs on clinical status as defined by the WHO ordinal scale for clinical improvement. DISCUSSION: In this trial, we target the thromboinflammatory response at multiple levels. We intensify the dose of low molecular weight heparins to reduce thrombotic complications. Aprotinin is a potent kallikrein pathway inhibitor that reduces fibrinolysis, activation of the contact pathway of coagulation, and local inflammatory response. Additionally, aprotinin has shown in vitro inhibitory effects on SARS-CoV-2 cellular entry. Because the excessive thromboinflammatory response is one of the most adverse prognostic factors in COVID-19, we will add anakinra, a recombinant interleukin-1 receptor antagonist, to the regimen in case of severely increased inflammatory parameters. This way, we hope to modulate the systemic response to SARS-CoV-2 and avoid disease progressions with a potentially fatal outcome. TRIAL REGISTRATION: The EU Clinical Trials Register 2020-001739-28 . Registered on April 10, 2020.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Vanassche T, Engelen MM, Van Thillo Q, et al. A randomized, open-label, adaptive, proof-of-concept clinical trial of modulation of host thromboinflammatory response in patients with COVID-19: the DAWn-Antico study. Trials. 2020. PMID: 33298149. doi:10.1186/s13063-020-04878-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。